[EN] IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR PRÉPARER DU 4-MÉTHYL-2-(4-(2-MÉTHYLPROPYLOXY)-3-CYANOPHÉNYL)-5-THIAZOLECARBOXYLATE D'ÉTHYLE
申请人:NATCO PHARMA LTD
公开号:WO2012032528A3
公开(公告)日:2015-10-29
PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE
申请人:Kompella Amala
公开号:US20130172571A1
公开(公告)日:2013-07-04
Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid (Febuxostat, I(A)) is approved under the trademark Uloric® by the US Food and Drug Administration for the treatment of hyperuricemia and gouty arthritis.